Merck acquires Terns for $6.7B in oncology bet

Good morning, healthcare professional.

Major dealmaking activity is reshaping the oncology landscape as Merck announces a nearly $7 billion acquisition, while the FDA delivers back-to-back approvals for rare disease therapies after a string of rejections. Meanwhile, medical education faces a significant policy shift as accreditation requirements around health equity are quietly removed.

These developments signal both opportunity and uncertainty across the healthcare sector. From billion-dollar bets on leukemia treatments to regulatory wins for underserved patient populations, today's news highlights the industry's continued evolution amid changing political and scientific landscapes.

In today's healthcare digest:

• Merck's $6.7 billion acquisition of Terns Pharmaceuticals targets differentiated leukemia assets
• FDA approves Denali's Hunter syndrome therapy, breaking rare disease rejection streak
• Corcept wins FDA nod for ovarian cancer drug after previous setback
• Medical school accreditor drops health equity teaching requirements under political pressure

Merck Bets $6.7 Billion on Terns Leukemia Portfolio

The Recap: Merck announced plans to acquire Terns Pharmaceuticals for $6.7 billion, focusing on the biotech's oncology pipeline. The deal has sparked debate among analysts about whether the price tag signals the start of a broader biotech bidding war.

Unpacked:

• The acquisition centers on Terns' lead asset, a differentiated treatment for acute myeloid leukemia currently in development.
• At nearly $7 billion, the deal represents one of the largest oncology-focused acquisitions announced this year.
• Industry observers suggest the premium valuation may encourage other major pharma companies to pursue similar transactions.

FDA Approves Denali's Hunter Syndrome Drug

The Recap: The FDA granted approval to Denali Therapeutics' treatment for Hunter syndrome, a rare genetic disorder. The decision breaks a recent pattern of rejections for rare disease therapies and provides new hope for affected families.

Unpacked:

• Hunter syndrome is a rare metabolic disorder that primarily affects boys, causing progressive damage to organs and tissues.
• The approval follows several high-profile FDA rejections of rare disease treatments in recent months.
• Denali's success may signal renewed regulatory momentum for therapies targeting ultra-rare conditions with limited options.

Corcept Wins FDA Approval for Ovarian Cancer Drug

The Recap: Corcept Therapeutics secured FDA approval for Lifyorli in ovarian cancer, marking a comeback after a previous regulatory setback. The drug addresses a patient population with few treatment alternatives.

Unpacked:

• Lifyorli targets a specific subset of ovarian cancer patients who have exhausted standard therapeutic options.
• The approval comes after the FDA previously rejected the same compound for a different indication.
• Corcept's persistence in pursuing alternative development pathways demonstrates the value of strategic regulatory planning.

Medical Schools Drop Health Equity Requirements

The Recap: The Liaison Committee on Medical Education, which accredits U.S. medical schools, has removed requirements for teaching about health equity and structural competency. The decision follows mounting political pressure against diversity, equity, and inclusion initiatives in medical education.

Unpacked:

• The accreditation change affects how future physicians are trained to address health disparities across patient populations.
• Critics argue the shift may reduce doctors' preparedness to serve diverse communities and understand social determinants of health.
• Supporters contend medical schools should focus on clinical competencies rather than what they characterize as political curricula.

The Shortlist

• Rocket Pharma won FDA approval for its gene therapy treating a rare immune disorder called LAD-1.

• Recordati confirmed it is evaluating a $12.6 billion buyout offer from private equity firm CVC Capital.

• Takeda announced plans to cut $1.3 billion in costs through further restructuring efforts.

• Sarepta Therapeutics reported early positive data for RNAi drugs targeting rare muscular dystrophy conditions.

• Beam Therapeutics posted encouraging results for its base editing treatment in alpha-1 antitrypsin deficiency.